| Original language | English |
|---|---|
| Pages (from-to) | 649-658 |
| Number of pages | 10 |
| Journal | Osteoporosis International |
| Volume | 30 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 2019 |
Keywords
- Cost-effectiveness
- Economic evaluation
- Osteoporosis
- Risedronate
- Treatment
- QUALITY-OF-LIFE
- ECONOMIC-EVALUATION
- INTERVENTION THRESHOLDS
- ORAL BISPHOSPHONATES
- EXCESS MORTALITY
- HIP FRACTURE
- PERSISTENCE
- ADHERENCE
- HOSPITALIZATION
- BURDEN
Cite this
}
Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France. / Hiligsmann, M.; Reginster, J. -Y.
In: Osteoporosis International, Vol. 30, No. 3, 03.2019, p. 649-658.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Cost-effectiveness of gastro-resistant risedronate tablets for the treatment of postmenopausal women with osteoporosis in France
AU - Hiligsmann, M.
AU - Reginster, J. -Y.
PY - 2019/3
Y1 - 2019/3
KW - Cost-effectiveness
KW - Economic evaluation
KW - Osteoporosis
KW - Risedronate
KW - Treatment
KW - QUALITY-OF-LIFE
KW - ECONOMIC-EVALUATION
KW - INTERVENTION THRESHOLDS
KW - ORAL BISPHOSPHONATES
KW - EXCESS MORTALITY
KW - HIP FRACTURE
KW - PERSISTENCE
KW - ADHERENCE
KW - HOSPITALIZATION
KW - BURDEN
U2 - 10.1007/s00198-018-04821-7
DO - 10.1007/s00198-018-04821-7
M3 - Article
VL - 30
SP - 649
EP - 658
JO - Osteoporosis International
JF - Osteoporosis International
SN - 0937-941X
IS - 3
ER -